Bioengineered Renal Cell Therapy Device for Clinical Translation
نویسندگان
چکیده
منابع مشابه
Renal Preservation Therapy for Renal Cell Carcinoma
Renal preservation therapy has been a promising concept for the treatment of localized renal cell carcinoma (RCC) for 20 years. Nowadays partial nephrectomy (PN) is well accepted to treat the localized RCC and the oncological control is proved to be the same as the radical nephrectomy (RN). Under the result of well oncological control, minimal invasive method gains more popularity than the open...
متن کاملImaging: guiding the clinical translation of cardiac stem cell therapy.
Stem cells have been touted as the holy grail of medical therapy, with promises to regenerate cardiac tissue, but it appears the jury is still out on this novel therapy. Using advanced imaging technology, scientists have discovered that these cells do not survive nor engraft long-term. In addition, only marginal benefit has been observed in large-animal studies and human trials. However, all is...
متن کاملGuiding the Clinical Translation of Cardiac Stem Cell Therapy
Stem cells have been touted as the holy grail of medical therapy, with promises to regenerate cardiac tissue, but it appears the jury is still out on this novel therapy. Using advanced imaging technology, scientists have discovered that these cells do not survive nor engraft long-term. In addition, only marginal benefit has been observed in large-animal studies and human trials. However, all is...
متن کاملBioengineered Surfaces and Hydrogels for Specific Cell
Microfluidic affinity-based cell capture devices are presently able to isolate specific cell populations from heterogenous samples, such as whole blood. The impact of this potentially powerful technology, however, is restricted by the fact that there is no reliable method to release the target cells from the capture surface while preserving their integrity. This work presents the development an...
متن کاملSystemic therapy for advanced renal cell carcinoma.
Renal cell carcinoma (RCC) accounts for approximately 3% of all cancers and is refractory to cytotoxic chemotherapy - immunotherapy has until recently been the standard of care for advanced disease. Randomised trials reported in the last 5 years have demonstrated that a number of agents including the monoclonal antibody, bevacizumab, and the kinase inhibitors - sorafenib sunitinib, temsirolimus...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: ASAIO Journal
سال: 2017
ISSN: 1058-2916
DOI: 10.1097/mat.0000000000000485